ARIAD Receives Seventh Patent On Its ARGENT Gene Regulation Technology.Business & Health Editors CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 29, 2000 ARIAD ARIAD Allison Research Index of Art and Design Comments On Joint U.S. - U.K. Policy Statement On Broad Availability of Genomic Data and Patenting of Gene-Based Inventions ARIAD Pharmaceuticals, Inc. (Nasdaq: "ARIA") today announced the issuance of its seventh patent in a series of U.S. patents covering use of the ARIAD Regulated Gene Expression Technology (ARGENT ar·gent n. 1. Heraldry The metal silver, represented by the color white. 2. Archaic Silver or something resembling it. (TM)) system for pharmaceutical regulation of cellular processes, including gene expression and protein production. The claims in the newly issued patent (U.S. Patent No. 6,043,082) further expand ARIAD's scope of intellectual property relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc ARGENT and cover proprietary materials for directing proteins to specific locations within the cell using small-molecule drugs that cause dimerization, or clustering, of proteins. By causing transcription factors to localize lo·cal·ize v. lo·cal·ized, lo·cal·iz·ing, lo·cal·iz·es v.tr. 1. To make local: decentralize and localize political authority. 2. in particular cellular compartments, small-molecule Dimerizer Drugs(TM) can regulate the expression of therapeutic genes, such as erythropoietin erythropoietin /eryth·ro·poi·e·tin/ (-poi´e-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production and interferons. "The issuance of our seventh patent covering our ARGENT platform technology further strengthens our intellectual property position in regulated gene therapy. Our efforts have been directed towards understanding the function of genes in disease and utilizing this information to develop gene therapy products, regulated by small-molecule drugs," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. Dr. Berger added, "our business does not involve generation or sale of large amounts of gene sequence data. We concur with the joint U.S. - U.K. policy statement made earlier this month on the need for broad availability of raw, human gene sequence data from the international Human Genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. Project and support for intellectual property protection of gene-based inventions. Wider access to human genome databases should benefit ARIAD's product development and commercialization plans." "We have 96 patents and patent applications in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , including 19 issued patents, seven of which now cover our proprietary ARGENT gene regulation system. We will continue to seek patent protection on our new products, enabling technologies and genomics tools," said David Berstein, Esq., chief patent counsel of ARIAD. Copies of the new ARIAD Patent (U.S. Patent No. 6,043,082), as well as the previously issued patents on ARGENT (U.S. Patent Nos. 5,830,462; 5,834,266; 5,869,337; 5,871,753; 5,994,313; and 6,011,018), are available on the World Wide Web at http://www.uspto.gov/web/menu/search.html. ARIAD Pharmaceuticals (www.ariad.com) is a leader in the discovery and development of proprietary platform technologies and small-molecule therapeutic products based on gene regulation and signal transduction Signal transduction The transmission of molecular signals from a cell's exterior to its interior. Molecular signals are transmitted between cells by the secretion of hormones and other chemical factors, which are then picked up by different cells. . These enabling technologies distinguish the gene therapy and protein therapy products being developed by the Company and also may be licensed to pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. for use in their research and product development programs. ARIAD also is developing orally administered small-molecule drugs to inhibit signal transduction pathways that are critically involved in major diseases. Some of the matters discussed in this news release are forward-looking statements that involve risks and uncertainties. For example, there can be no assurance that if a patent is issued, any such patent would be enforceable or provide meaningful protection. Other risks and uncertainties include, but are not limited to, risks and uncertainties regarding the Company's preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. , the ability of the Company to conduct clinical trials of its products and the success of such trials, as well as risks and uncertainties relating to economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on our collaborators and other factors under the heading "Cautionary Statement Regarding Forward-Looking Statements" in ARIAD's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended December 31, 1999 filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion